Press release: VivoPlex expands its Board with appointment of new Non-Executive Director

VivoPlex expands its Board with appointment of new Non-Executive Director
David Wilkinson brings experience of strategy & governance in growth firms

 

Southampton, UK, April 25, 2019 – David Wilkinson, an experienced Director of entrepreneurial businesses, has been appointed a Non-Executive Director at VivoPlex Group Ltd, a leader in real time and accurate intra-uterine monitoring. He will play a key role in helping the company meet its growth and financing goals as its biosensor technology continues to develop.

Training as a Chartered Accountant with Ernst & Young (EY) and becoming a senior partner, David worked extensively within the firm for over three decades supporting growth companies. This included working as an audit partner for entrepreneurial businesses and taking many companies through fund raising, M&A, IPOs and other exits. He is Chairman of private property company CH Bailey plc, Senior Independent NED at AIM-listed digital marketer Be Heard Group plc, and an NED at Goal Group Ltd, a private reclamation service provider.

VivoPlex is a spin-out from the University of Southampton, and recently closed a £3m Series A fundraising round for further development its intra-uterine monitor. The product is expected to enter a clinical feasibility study (supported by the UK NIHR’s i4i Programme in a joint project with the University of Southampton) later this year.

Dr Chris Dickson, Chairman of VivoPlex Ltd, said, ‘We are delighted to welcome David, with his wealth of experience and perspective, to the Board. As VivoPlex develops its product and the business expands, his finance and governance expertise in growth businesses will be invaluable.’

David Wilkinson, NED of VivoPlex, said ‘I’ve been really impressed by the potential of VivoPlex’s wireless biosensor technology across a range of applications, and the data the company has generated so far. It’s great to be joining VivoPlex at this exciting stage of its development and I look forward to working with the team to take it through the next stages of growth.’

–ENDS–

Photograph available on request.

For further information, please contact:
Joanna Smart, CEO
Tel: +44 (0) 2380 111555

Emma Palmer Foster, Communications
Tel: +44 (0) 7880 787185

info@vivoplex.com

Notes to editors

VivoPlex Group Ltd

VivoPlex is a leader in real time and accurate intra-uterine monitoring for the optimisation of fertility treatment and uterine health – transforming fertility through precision medicine. Its product is in development as the first insertable wireless device for the measurement of key uterine parameters – oxygen concentration, pH and temperature – in vivo. Better understanding of these levels in humans in real time and over the long term should enable improvement of the success rate of fertility treatment, currently 25-30%. Around 12% of women wishing to have a child experience subfertility, and the IVF market is growing at a CAGR of 11% (Allied Market Research 2017), driven by factors such as rising age at which women are having children and increasing disposable income globally. The VivoPlex product comprises an insertable monitor no bigger than an intra-uterine device (IUD or coil) plus a wearable in the form of washable, discreet briefs which provides wireless power to the device and transmits data to proprietary software for use by the fertility specialist. It has generated positive results in early studies, and has potential in a range of other applications. The company, which brings together a multidisciplinary team of clinical fertility experts and world-class biosensor and digital technology engineers with experienced corporate and business development executives, was established in 2015 as a spin-out from the University of Southampton. For more information please visit www.vivoplex.com.